Search Results - "Lemming, Ole M."

4.62 A SIX-MONTH OPEN-LABEL EXTENSION STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS by Findling, Robert L., MD, MBA, Robb, Adelaide S., MD, DelBello, Melissa P., MD, MS, Huss, Michael, MD, McNamara, Nora K., MD, Sarkis, Elias H., MD, Scheffer, Russell E., MD, Poulsen, Lis H., MD, Chen, Grace, PhD, Lemming, Ole M., MSc, Auby, Philippe, MD

“…Objectives: This 24-week open-label extension (OLE) of NCT01491035 (14- day, open-label, multidose, pharmacokinetic/safety study) investigated the long-term…”
Get full text

Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension by Kane, John M., Kinon, Bruce J., Forray, Carlos, Such, Pedro, Mittoux, Aurélia, Lemming, Ole M., Hertel, Peter, Howes, Oliver D.

“…Treatment resistance constitutes the highest burden of disease within schizophrenia. We hypothesized that the synergistic activity of Lu AF35700 at dopamine D1…”
Get full text

Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies by Chick, Jonathan, Andersohn, Frank, Guillo, Sylvie, Borchert, Kathrin, Toussi, Massoud, Braun, Sebastian, Haas, Jennifer S, Kuppan, Kavitha, Lemming, Ole M, Reines, Elin Heldbo, Tubach, Florence

“…Abstract Aims Two post-authorisation studies assessed the safety and persistence of patients’ use of nalmefene. Methods The START study (EUPAS5678) was a…”
Get full text

Measuring therapeutic efficacy in patients with Alzheimer's disease: role of instruments by Riepe, Matthias W, Janetzky, Wolfgang, Lemming, Ole M

“…Global cognitive scales and meta-analyses thereof are used to appraise therapeutic efficacy over a broad range of disease severity. Clinically, however,…”
Get more information

Sertindole in the long-term treatment of schizophrenia by Hale, Anthony S, Azorin, Jean M, Lemming, Ole M, Mæhlum, Eli

“…This study assessed the safety and tolerability of sertindole in the long-term treatment of schizophrenia. An open-label, noncomparative, flexible-dose study…”
Get full text